Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
March 08, 2022 09:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
February 15, 2022 07:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards
February 08, 2022 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
January 24, 2022 17:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 07, 2022 14:05 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
January 05, 2022 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Added to the NASDAQ Biotechnology Index
December 16, 2021 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
December 13, 2021 09:00 ET
|
Mustang Bio, Inc.
95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of...
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
December 09, 2021 08:30 ET
|
Mustang Bio, Inc.
Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage...
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 12, 2021 08:05 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...